Universe Pharmaceuticals Inc: updates and filings

UPCNASDAQHealthcare · Pharmaceutical Preparations

Price

$1.52

November 18, 2026

What Ploutos Investor adds for Universe Pharmaceuticals

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from FY2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The latest annual figures the company filed are for 2025, more than a year ago. Newer ones may be late.
  • A figure that did not match the numbers it is built from has been left out.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Jan 29, 2026 latest annual
  • Oct 9, 2026Filing
    FormEFFECT
  • Oct 6, 2026Current report (foreign company)
    Form6-K
  • Sep 29, 2026REGISTRATION STATEMENT
    FormF-3
  • Sep 3, 2026Current report (foreign company) (amendment)
    Form6-K/A
  • Sep 1, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Sep 1, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Sep 1, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Sep 1, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Sep 1, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Sep 1, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Sep 1, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Sep 1, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Sep 1, 2026Current report (foreign company)
    Form6-K
  • Jul 31, 2026Current report (foreign company)
    Form6-K
  • Jul 29, 2026Current report (foreign company)
    Form6-K
  • Jun 26, 2026Current report (foreign company)
    Form6-K
  • May 21, 2026Over-5% holder statement (active)
    FormSCHEDULE 13D
  • May 14, 2026Current report (foreign company)
    Form6-K
  • Apr 16, 2026Current report (foreign company)
    Form6-K
  • Feb 11, 2026Current report (foreign company)
    Form6-K
  • Jan 29, 2026Annual report (foreign company)for the period to Sep 30, 2025
    Form20-F
  • Jan 7, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Sep 3, 2025Current report (foreign company)
    Form6-K
  • Aug 26, 2025Current report (foreign company)
    Form6-K
  • Jul 29, 2025Current report (foreign company)
    Form6-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Apr 24, 2020.

The full analysis

What do Universe Pharmaceuticals's filings show?

The filings are where every one of Universe Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.